Group 1 - The company, Lianhuan Pharmaceutical (600513.SH), plans to increase the registered capital of its wholly-owned subsidiary, Lianhuan Pharmaceutical (Anqing) Co., Ltd., by 50 million RMB, raising it from 131.52 million RMB to 181.52 million RMB [1] - The purpose of this capital increase is to support the strategic development plan of Lianhuan (Anqing) and to meet its funding needs for product research and development, license acquisition, and production line upgrades [1] - This capital increase does not involve related party transactions, does not constitute a major asset restructuring, and does not require approval from the company's shareholders [1] Group 2 - The completion of the capital increase is subject to approval from the relevant state-owned asset authorities, indicating a regulatory requirement [1] - There is uncertainty regarding the operational status and profitability of Lianhuan (Anqing) following the capital increase [1]

证券代码：600513 证券简称：联环药业 公告编号：2026-009 增资标的名称：联环药业（安庆）有限公司 增资金额：以自有及自筹资金增资 5,000.00 万元人民币。 本次增资不涉及关联交易，亦不构成重大资产重组，无需提交公司股东会 审议。 本次增资对象为公司的全资子公司，整体风险可控，但仍受宏观经济、行 业环境、市场竞争等多种因素的影响，其经营状况和收益存在不确定性。同时本 次增资尚需获得国资有权部门审批通过，存在不确定性。公司将加强对联环（安 庆）的运营管理和风险管控，确保其合规、稳健、高效经营。敬请广大投资者理 性投资，注意投资风险。 一、增资情况概述 （一）增资的基本情况 江苏联环药业股份有限公司 关于对全资子公司增资的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （1）本次交易概况 为实现江苏联环药业股份有限公司（全文简称"公司"）整体战略目标，为 支持全资子公司联环药业（安庆）有限公司（全文简称"联环（安庆）"）实施其 战略发展规划，满足其在品种研发、批件购买和生产线改扩建等方面的关 ...

Market Performance - The chemical pharmaceutical sector increased by 1.41% on February 3, with Yiming Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up 1.29%, while the Shenzhen Component Index closed at 14127.1, up 2.19% [1] Top Gainers in Chemical Pharmaceutical Sector - Yiming Pharmaceutical (002826) closed at 20.98, up 9.27% with a trading volume of 269,200 shares and a transaction value of 559 million [1] - Yuandong Biological (688513) closed at 68.90, up 8.85% with a trading volume of 64,600 shares [1] - Nami Technology (688690) closed at 29.00, up 7.01% with a trading volume of 93,900 shares and a transaction value of 265 million [1] - Lianhuan Pharmaceutical (600513) closed at 20.15, up 5.94% with a trading volume of 162,200 shares and a transaction value of 323 million [1] Top Losers in Chemical Pharmaceutical Sector - Shuangbi Pharmaceutical (002038) closed at 6.41, down 7.10% with a trading volume of 801,300 shares and a transaction value of 511 million [2] - Haizhi Pharmaceutical (002653) closed at 47.50, down 5.47% with a trading volume of 90,200 shares and a transaction value of 430 million [2] - Nuo Cheng Jianhua (688428) closed at 21.13, down 3.78% with a trading volume of 163,500 shares [2] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 42.01 million from institutional investors, while retail investors saw a net inflow of 651 million [2] - The main capital inflow was observed in Yiming Pharmaceutical with 58.98 million, while it faced a net outflow of 58.77 million from retail investors [3] - Other notable inflows included Guangsheng Tang (300436) with 14.8 million from main capital, while it faced a net outflow of 95.56 million from retail investors [3]

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. has received the Drug Registration Certificate for Lidocaine Hydrochloride Gel from the National Medical Products Administration, marking a significant milestone in the company's product development and regulatory compliance [1][4]. Group 1: Drug Registration Certificate Details - The Drug Registration Certificate pertains to Lidocaine Hydrochloride Gel, which is indicated for local anesthesia during procedures requiring such intervention [1]. - The company is one of three domestic enterprises that have obtained this Drug Registration Certificate for the product [1]. - The estimated sales revenue for Lidocaine Hydrochloride Gel in national secondary hospitals and above is approximately 40.86 million yuan in 2024 [1]. Group 2: R&D Investment and Production Approval - As of the announcement date, the cumulative R&D investment for this project is approximately 7.27 million yuan (unaudited) [2]. - This is the first production license obtained by the company in 2026 [3]. Group 3: Impact on the Company - The acquisition of the Drug Registration Certificate for Lidocaine Hydrochloride Gel enhances the company's product line and is expected to improve its market competitiveness [4]. - The impact of this certificate on the company's near-term operating performance is not anticipated to be significant [4].

盐酸利多卡因凝胶适用于局麻药、经尿道施行检查和治疗需局部麻醉者。 截至目前，包括公司在内，国内共有三家企业取得该药品的《药品注册证书》。 2024 年全国二级以上医院盐酸利多卡因凝胶销售额约为 4,086.45 万元（数据 来源于摩熵·医药数据库）。 证券代码：600513 证券简称：联环药业 公告编号：2026-008 江苏联环药业股份有限公司 关于公司获得《药品注册证书》的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏联环药业股份有限公司（以下简称"公司"）于近日收到国家药品监 督管理局（以下简称"国家药监局"）核准签发的关于盐酸利多卡因凝胶（以 下简称"该药品"）的《药品注册证书》，现将相关情况公告如下： 二、药品的其他情况 1 药品名称 盐酸利多卡因凝胶 剂型 凝胶剂 规格 2%(10g:0.2g) 申请事项 药品注册（境内生产） 注册分类 化学药品 3 类 处方药/非处方药 处方药 受理号 CYHS2402656 证书编号 2026S00232 药品批准文号 国药准字 H20263193 上市许可持有人 名 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Lidocaine Hydrochloride Gel, which is expected to enhance its product line and competitiveness, although it is not anticipated to have a significant impact on recent performance [1] Group 1: Product Approval - The product is classified as a Class 3 chemical drug and is considered to have passed the consistency evaluation of generic drug quality and efficacy [1] - The registered specification of the drug is 2% (10g:0.2g) [1] Group 2: Financial Implications - Cumulative R&D investment in this project amounts to approximately 7.27 million yuan [1] - The estimated sales revenue for this product in secondary and higher-level hospitals across the country in 2024 is approximately 40.86 million yuan [1] Group 3: Strategic Impact - The approval of this product is expected to enrich the company's product line and enhance its competitive position in the market [1] - The company anticipates no major impact on its recent performance following this approval [1]

Group 1 - The company announced the progress of an asset purchase and related party transaction involving its wholly-owned subsidiary, Lianhuan Pharmaceutical (Anqing) Co., Ltd. [2] - The transaction was approved during the board meeting on September 12, 2025, and the subsequent shareholder meeting on September 30, 2025, with a purchase price of 74.5 million RMB (excluding tax) for certain buildings and land use rights [2] - Lianhuan (Anqing) has paid 50% of the transaction amount and related taxes, and has completed the necessary property rights transfer procedures, obtaining the property certificate from the Anqing Natural Resources and Planning Bureau [3]

江苏联环药业股份有限公司（以下简称"公司"或"联环药业"）于 2025 年 9 月 12 日召开第九届董事会第十五次临时会议，并于 2025 年 9 月 30 日召开 2025 年第三次临时股东会审议通过了《关于全资子公司购买资产暨关联交易的 议案》，同意公司全资子公司联环药业（安庆）有限公司（以下简称"联环（安 庆）"）向公司控股股东江苏联环药业集团有限公司控股孙公司普林斯（安庆）医 药科技有限公司（以下简称"普林斯（安庆）"）以 7,450.00 万元人民币（不含 税）的交易价格购买部分房屋建(构)筑物及土地使用权，具体内容详见披露在上 海证券交易所网站 www.sse.com.cn 的《联环药业第九届董事会第十五次临时会 议决议公告》（公告编号：2025-070）、《联环药业关于全资子公司购买资产暨关 联交易的公告》（公告编号：2025-072）、《联环药业 2025 年第三次临时股东会决 议公告》（公告编号：2025-077）。 二、交易的进展情况 联环（安庆）已按合同要求向普林斯（安庆）支付部分交易款项（50%）及 相关税费缴纳，并完成房屋建（构）筑物及土地使用权的不动产权的变更手续， 近日，联环（ ...

Core Viewpoint - The company announced that the Phase III clinical trial of LH-1801 is expected to unblind in the first quarter of 2026, and there are currently no undisclosed matters that need to be reported [1] Group 1 - The company is actively engaging with investors through an interactive platform, indicating transparency in communication [1] - The company emphasizes the uncertainties associated with innovative drug development, which may impact investment decisions [1] - The company will provide timely updates on any progress related to LH-1801 and encourages investors to monitor relevant announcements [1]

1月24日，江苏联环药业股份有限公司（简称"联环药业"）披露2025年全年业绩预告，公司预计归属于 上市公司股东的净利润为-9900万元至-8300万元，同比下降217.63%至198.62%，由盈转亏。此次业绩亏 损，也是联环药业上市以来的首次年度亏损。 因垄断原料药收超6000万元罚单 联环药业的业绩崩塌，早已埋下伏笔。2024年，公司业绩开始下滑，实现营业收入21.60亿元，同比微 降0.63%；归母净利润8416万元，同比减少37.66%；扣非后归母净利润4986.80万元，同比下滑56.89%。 2025年，联环药业由盈转亏。根据业绩预告，联环药业全年归母净利润预计亏损8300万元至9900万元， 较上年同期减少1.67亿元至1.83亿元，降幅突破200%；扣非后归母净利润预计亏损3250万元至3900万 元，同比减少8236.8万元至8886.8万元。 一场突如其来的反垄断罚单直接影响了超6000万元的公司净利润。去年6月，联环药业收到天津市市场 监督管理委员会下发的《行政处罚决定书》。天津市市场监督管理委员会认为，联环药业与具有竞争关 系的经营者，以垄断协议形式变更、固定地塞米松磷酸钠原料药价格 ...